Biosimilars to Avastin and Herceptin Head for US Market Biosimilars to Avastin and Herceptin Head for US Market

Two new biosimilars, bevacizumab and trastuzumab, were unanimously recommended for approval by an FDA oncologic advisory committee.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news